Jeffrey S. Glenn - Dec 22, 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role
Director
Signature
/s/ Sriram Ryali, Attorney-in-Fact
Stock symbol
EIGR
Transactions as of
Dec 22, 2022
Transactions value $
$127,950
Form type
4
Date filed
12/27/2022, 04:31 PM
Previous filing
Mar 11, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EIGR Common Stock Purchase $128K +100K +121.43% $1.28 182K Dec 22, 2022 Direct F1
holding EIGR Common Stock 5K Dec 22, 2022 By spouse
holding EIGR Common Stock 460 Dec 22, 2022 By son
holding EIGR Common Stock 151K Dec 22, 2022 By Eiger Group International, Inc. F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 Shares are held by Eiger Group International, Inc. ("EGI"). The Reporting Person is the Chief Executive Officer of EGI and has sole power to vote and sole power to dispose of shares directly owned by EGI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.